OncoMatch/Clinical Trials/NCT06430736
PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)
Is NCT06430736 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Tocilizumab before CAR-T cell infusion and Tocilizumab at emerging CRS for myeloma.
Treatment: Tocilizumab before CAR-T cell infusion · Tocilizumab at emerging CRS — Despite the consequent use of Tocilizumab together with conventional antipyretics at early/first signs of emerging CRS, CRS (and eventually the subsequent development of ICANS) remain a major concern for patients. This study aims to identify safety and efficacy of prophylactic Tocilizumab treatment. In particular, to explore whether prophylactic Tocilizumab treatment can decrease the incidence and severity of CRS (and subsequent eventual neurotoxicity) following CAR-T-treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Prior therapy
Must have received: CAR-T cell therapy — planned
Patients planned to receive commercial CAR-T treatment for all registered indications comprising lymphomas, leukemias or myeloma
Cannot have received: IL-6 inhibitor (tocilizumab)
Previous Tocilizumab treatment within 3 months prior to CAR-T infusion
Cannot have received: investigational compound
treatment with an investigational compound within 8 weeks prior to CAR-T infusion
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify